Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.


Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

Successful insomnia treatment may require nothing more than a placebo

Bristol-Myers Squibb appoints three new independent directors

Online pharmacies could fuel antibiotic resistance

Vitamin D protects against colds and flu, finds major global study

AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada

Your computer can help scientists search for new childhood cancer treatments

DNA computer brings 'intelligent drugs' a step closer

Spider web of cancer proteins reveals new drug possibilities

Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasi …

Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generati …

Immune cell study prompts rethink on how to tackle infections

Tumor-targeting system uses cancer's own mechanisms to betray its location

Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and mee …

How eating less can slow the aging process

Inducing an identity crisis in liver cells may help diabetics

ImmusanT's celiac disease immunotherapy passes first clinical test

Argos kidney cancer vax fails phase 3 futility review, future in doubt

Cancer startup PMV Pharma gains impressive $74M B round

After Merck KGaA rejection, Apitope advances MS drug on strength of phase 2a safety, lesion reductio …

VBL posts additional data from phase 2 thyroid cancer trial

FDA accepts Pfizer’s blood cancer candidate for speedy review

Cidara fails phase 2 study, drops med in vulvovaginal candidiasis

Sarepta sells Exondys 51 PRV to Gilead for $125M

Cancer player Nordic Nanovector stokes takeover talk

Trial shows ArmaGen biologic improves cognition in Hurler syndrome patients

Daiichi, ArQule’s struggling tivantinib fails in phase 3 liver cancer test

British investment firm Arix Bioscience hits £100M IPO target

Takeda, TiGenix stem cell therapy shows sustained effect

Sage Therapeutics fuels, then dampens, its own M&A rumors

Gilead sells phase 2 addiction drug to ex-CVT team

China issues five-year plans on food and drug safety

Amphastar plunges on receipt of CRL for opioid overdose drug

EFPIA poaches new DG from fellow trade group

After positive top-line results of pain med, Trevena shares fall 30%

Sarepta sells FDA priority voucher for $125 million

Shares hit by Bayer results but pharma growth continues

Events at Bristol-Myers raise likelihood of takeover

FDA accepts filing for Pfizer’s investigational leukemia drug

CETA has potential to strengthen European manufacturing base of the generic, biosimilar sectors

Akihisa Nabeshima elected new president of Teijin Pharma

Bayer shares down despite beating 4th-qtr expectations

NICE draft guidance rejects cabozantinib for kidney cancer

Setting up a successful corporate giving program

Biocad and Roche continue legal battles in Russia

EyeGate deal could be worth over $100 million

Medical News Today: Preeclampsia raises risk of heart disease, heart failure

Medical News Today: Life expectancy set to rise in industrialized countries

Medical News Today: HIV rash: What does it look like and how long does it last?

Medical News Today: Is shrimp high in cholesterol? Nutritional and heart health information

Medical News Today: Exercise is best for reducing breast cancer recurrence

Medical News Today: New 'late-life cycler' circadian genes linked to aging and stress

Medical News Today: What is best to eat and drink when you have a sore throat?

Medical News Today: Children inherit around 40 percent of parents' BMI

Medical News Today: What are the benefits and risks of testosterone therapy? Studies investigate

Medical News Today: Early miscarriage threat from Listeria may be serious

Medical News Today: HIV: Early signs and symptoms

Medical News Today: Lou Gehrig's disease: Mercury in fish, seafood could be risk factor

Medical News Today: What increases the chance of getting HIV?

Medical News Today: Heavy drinking may raise cardiovascular risk by aging the arteries

Medical News Today: Natural and home remedies for a sore throat

Priority review for Pfizer’s ALL drug

MSD, Wayra unveil Velocity Health winners

EU nod for Roche’s lung cancer drug Alecensa

Final NICE yes for Amicus’ Fabry disease drug

BMA report highlights NHS bed crisis

NHS books £886m year-to-date deficit

NICE draft guidelines reject Ipsen’s Cabometyx

AstraZeneca’s Lynparza hits breast cancer trial targets

Biosimilar Inflectra matches Remicade efficacy in trial

Novartis, NHS joint working pact delivers new eye service

Mereo’s brittle bone drug joins EU’s adaptive pathways scheme

Nominations and entries for Sales Manager of the Year are open

Baxalta buy drives huge leap in Shire’s Q4 sales

Mixed results for Pfizer’s Xeljanz in RA trial

Liverpool Uni leads clinical trial of promising osteoarthritis drug

More News